Monitor for near-term selling activity by PIPE investors and Maxim Partners, which could increase float and create downward pressure on LBRX shares. The lack of proceeds to the company distinguishes this from a traditional follow-on offering.
Price Chart
Executive Summary
The SEC has declared effective LB Pharmaceuticals' S-1 registration, enabling the resale of up to 4,778,491 shares of common stock by selling stockholders. This includes shares from a February 2026 private placement and warrants exercised in March 2026. The company will not receive proceeds from these sales except for nominal warrant exercise fees.
Key Facts
- S-1 registration effective as of April 14, 2026, allowing resale of up to 4,778,491 shares
- Selling stockholders include PIPE investors from a February 2026 private placement and Maxim Partners LLC
- Company will not receive proceeds from the resale, except nominal $0.0001 per share from warrant exercises
- Stock symbol LBRX, last reported price $25.69 on April 2, 2026
- Company is classified as an emerging growth company and smaller reporting company
Financial Impact
Up to $122.7 million in potential market overhang based on 4,778,491 shares at $25.69 per share, though actual selling pressure depends on timing and volume
Risk Factors
- Potential share price pressure from immediate or rapid selling by PIPE investors
- Increased volatility as previously restricted shares enter public float
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001186 |
| Document: 9999999995-26-001186-index.html | 9999999995-26-001186 |
| Document: 9999999995-26-001186.txt | 9999999995-26-001186 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $39.83 (+14.49%) |
Oct 6, 2026 21d ago | EFFECT | $34.26 | awaiting T+60 | — | $39.83 (−16.26%) |
Sep 15, 2026 6w ago | 8-K | $43.04 | awaiting T+60 | — | $39.83 (−7.46%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $39.83 (−16.18%) |
Aug 11, 2026 11w ago | 8-K | $45.33 | awaiting T+60 | — | $39.83 (−12.13%) |
Aug 11, 2026 11w ago | Press Release | $45.33 | awaiting T+60 | — | $39.83 (−12.13%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $39.83 (+2.13%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.83 (+11.13%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.83 (+11.13%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $39.83 (+39.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers